Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
Lilly plans to hire approximately more than 1,000 new highly-skilled team members
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
 
        Subscribe To Our Newsletter & Stay Updated